Cargando…

Colorectal cancer screening with fecal occult blood test: A 22-year cohort study

The aim of the present study was to investigate the efficacy of colorectal cancer (CRC) screening with a three-tier fecal occult blood test (FOBT) in the Chinese population. The study was performed between 1987 and 2008 at the Beijing Military General Hospital, in a cohort of army service males and...

Descripción completa

Detalles Bibliográficos
Autores principales: JIN, PENG, WU, ZI-TAO, LI, SHI-RONG, LI, SHU-JUN, WANG, JI-HENG, WANG, ZHI-HONG, LU, JIAN-GUO, CUI, XIN-JUAN, HAN, YING, RAO, JIANYU, SHENG, JIAN-QIU
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789016/
https://www.ncbi.nlm.nih.gov/pubmed/24137374
http://dx.doi.org/10.3892/ol.2013.1402
Descripción
Sumario:The aim of the present study was to investigate the efficacy of colorectal cancer (CRC) screening with a three-tier fecal occult blood test (FOBT) in the Chinese population. The study was performed between 1987 and 2008 at the Beijing Military General Hospital, in a cohort of army service males and females aged >50 years. Between 1987 and 2005, a three-tier screening program, comprising guaiac-based FOBTs (gFOBTs), followed by immunochemical FOBTs for positive guaiac test samples and then colonoscopy for positive immunochemical test subjects, was performed annually. The cohort was followed up until 2008. The cohort included 5,104 subjects, of which, 3,863 subjects participated in screening (screening group) and 1,241 did not (non-screening group). The two groups did not differ in age, gender or other major risk factors for colon cancer. Overall, 36 CRCs occurred in the screening group and 21 in the non-screening group. Compared with the non-screening group, the relative risk for the incidence and mortality of CRC was 0.51 [95% confidence interval (CI), 0.30–0.87] and 0.36 (95% CI, 0.18–0.71), respectively, in the screening group. The general sensitivity of this three-tier FOBT was 80.6% (95% CI, 65.3–91.1). Thus, annual screening using the three-tier FOBT program may reduce the CRC incidence and mortality rate.